#ASCO25 trials suggest carboplatin may be safely omitted from neoadjuvant therapy in many HER2+ early breast cancers. neoCARHP showed non-inferior pCR without carboplatin and fewer side effects. CompassHER2-pCR confirmed strong THP efficacy, especially in ER− tumors.
#bcsm @ascocancer.bsky.social

Are serial liquid biopsies finally ready for prime time?

If #camizestrant is approved based on #SERENA-6, it would mark the first therapy triggered by a rising #ESR1 mutation before visible recurrence.

That means #ctDNA won’t just monitor—it could guide treatment.

@ascocancer.bsky.social
#bcsm

New hope for hormone-resistant breast cancer?
VERITAC-2 tests a next-gen PROTAC therapy targeting ESR1 mutations.
Breakthrough science at #ASCO25 🎯

@ascocancer.bsky.social @ascopost.bsky.social @erikahamilton9.bsky.social